Trial
NCT02499978
Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Stanford University
Collaborators
Janssen Scientific Affairs, LLC; University of Colorado, Denver
Condition
HIV/AIDS
Intervention
Darunavir/Cobicistat
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-09